TheEdgeResearch
Home / Stocks / CNGGF

Cann Group Limited (CNGGF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$3.3M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.11
52-Wk Range
0.0015-0.02
CEO
Jennifer Lee Pilcher
Country
AU
Currency
USD

Cann Group Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Mildura, VIC, AU. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3.3M. On trailing twelve-month figures it carries a trailing P/E of 0.30, a net margin of 237.1%. Its beta of 0.11 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
0.30
Price / Sales
0.41
Price / Book
0.07
EV / EBITDA
-3.67
Gross margin
-94.1%
Operating margin
-131.6%
Net margin
237.1%
Return on equity
—
Debt / equity
0.59
Current ratio
0.99
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
98
IPO date
2021-01-08
Headquarters
Mildura, VIC, AU
About Cann Group Limited

Cann Group Limited specializes in the end-to-end process of bringing medicinal cannabis to market. Its activities span from genetic development and cultivation to product manufacturing, clinical trials, and ultimately, the supply of therapeutic cannabis for both Australian consumption and international export. The company holds specific licenses enabling it to conduct research and grow cannabis for human medicinal and scientific study. Founded in 2014, Cann Group Limited operates out of its base in Port Melbourne, Australia.

Comparable companies

Cann Group Limited is most often compared with the following Healthcare names:

AVTBFCLABFCPIVFCTABFLIFDRPNRFRVVTFSTHZFTGIFFTNRG
More research on CNGGF
CNGGF technical analysis CNGGF TheEdge Score Compare against peers
Open full interactive analysis & DCF →